Table 3 Moderate vs deep neuromuscular blockade

	level of NMB	Baseline o	haracter	istics of study population		surgical chracteristics		anaesthesic background			Outcomes		
		n	ASA	Age	Sex (m/f)	Procedure	Technique	Hypnotic	Volatile	Surgical conditions	Pain	Perioperative Complications	
Bacte S, et al ⁴⁵	moderate (TOF 1-2)	30	1 - 111	41 (13)		Gastric bypass	Laparascopy	propofol -remi		quality of surgical exposure, 5 point rating scale DMMB 4.2±1, MNMB 3.9±1.1 NS); number of intra-abdominal pressure increases > 18 cm H2O (DNMB 0.2±0.9, MNMB 0.3±1.0, NS); duration from skin incision to skin closure (DNMB 61.3±15.1, MNMB 70.6±20.8, NS)	not reported	not reported	
	deep (PTC 1-2)	30	1 - 111	42 (11)		Gastric bypass	Laparascopy						
Barrio J, et al ⁴⁶	moderate (TOF 1-3)	90	1-11	unclear	unclear	Laparascopic cholecystectomy	Laparascopy	propofol group 1 and 2, unclear for group 3	unclear	Group 1 low- pressure pneumoperitone um, moderate NMB TOF 1-3, group 2 low- pressure pneumoperitone um with deep NMB PTC 1-5; Group 3 standard pressure (12 mm Hg), standard anagement anesthesist's choice; Surgical conditions 4 point scale at 3 time points: surgical field exposure (group 1 96.7, Ng); dissection of the gallbladder (group1 90% group 2 89,6); extraction- closure(group 1 89.6%, group 2	not reported	not reported	

										92.3%);; Group 3 versus group 2: greater percentage of good surgical conditions during standard pressure pneumoperitone um; conclusion BNMB not superior to MNMB; IAB better conditions with normal pressure pneumoperitone um,		
	deep (1-5 PTC)	90	I-II	unclear	unclear	Laparascopic cholecystectomy	Laparascopy			anny		
Barrio J, et al ⁴⁷	moderate (TOF 1-3)	76	ы	unclear	unclear	unclear	Laparascopy	Propofol		Pneumoperitone um 8 mm Hg versus 12, MNMB TOF 1-3, DNMB PTC< 5; Volume of CO2 insufflation during establishment of pneumoperitone um (41 patients, DNMB 8mm: 2.81±1.13, MNMB 8mm 2.24±1.1, L CO2, P<0.001; DNMB 12 mm: 4.09±1.31 MNMB 12 mm 3.52±1.31 L CO2, P<0.001) and skin-sacral promontory distance (35 patients), DNMB 8 mm 12.16±1.51 cm, MNMB 8 mm 11.78±1.52 cm, P=0.002; DNMB 12 mm 13.8±1.81, MNMB 12 mm 13.8±1.81, mm 13.8±1.81, mm 13.8±1.81, mm 13.8±1.81, mm 13.34±1.87 cm, P<0.001	not reported	not reported
	deep (PTC<5)	76	I-II	unclear	unclear	unclear	Laparascopy					
Blobner M, et al ⁴⁸	no NMB	57	1 - 111	18-75 yrs	(8m/17f)	Laparascopic cholecystectomy	Laparascopy		Desflurane	surgical conditions on a visual analog.	No difference in pain 24 h	No difference inFVC and PEF

										Scale (0-100); Significant difference between DNMB and no NMB, P<0.001, difference between groups 36 (CI 20-53), significant improvement after 0.3mg/kg rocuronium (see fig 1 p 631); Intraoperative adverse evnets No NMB 12/25 DNMB 1/25, P<0.001 (see table 2 p 631)		
	deep (TOF 0)	57	1 - 111	18-75 yrs	(7m/18f)	Laparascopic cholecystectomy	Laparascopy		Desflurane			
Bruintjes MHD, et al ⁴⁹	moderate (TOF 1-3)	51	uncle ar	56.6 +/- 9.7	24m, 27f	g laparoscopic donor nephrectomy (LDN)	Laparascopy	remifentanil and propof	lc	not measured	Q of recovery score 40: DNMB 169'Û, MNMB 169±15, NS; secondary analysis improved pain scores with DNMB; impossible to summarize;	no difference in postoperative complications
	deep (PTC 1-3)	50	uncle ar	55.7 +/- 10.2	21m, 29f	g laparoscopic donor nephrectomy (LDN)	Laparascopy	remifentanil and propof	ol			
Choi BM, et al ⁵⁰	moderate (TOF 1-2)	49	I - III	58 (51-61)	33m, 16f	laparoscopic gastrectomy	Laparascopy	propofol and remifentanil		Outcome VAS (0- 10) pain score and oxycodone effective dose; NO difference between DNMB and MNMB in oxycodon doses, 8 mg in both groups	No difference in wound pain and shoulder pain	not reported
	deep (PTC 1-2)	51	1 - 111	58 (49-63)	35m, 16f	laparoscopic gastrectomy	Laparascopy	propofol and remifentanil				
Dubois PE et al ⁵¹	moderate (unclear)	50	1-11	51.7 +/- 10.9	50f	aparoscopic hysterectomy	Laparascopy		desflurane general anaesthesia	DNMB: TOF-2, versus shallow NMB intubating dose, further dose only if surgical conditions grade 4. Surgical fiels 1 (excellent) - 4 (unacceptable); significant improvement in	not reported	not reported

		1	ı	I	l	<u> </u>		1		surgical field		
										scores in the		
										DNMB group compared to		
										shallow block		
										(not MNMB), see		
										results page 433 and fif 2-3 page		
										434)		
									desflurane			
	deep (unclear)	50	1-11	49.9 +/- 9.8	50f	aparoscopic hysterectomy	Laparascopy		general anaesthesia			
									diaconicola	Intraoperative	not reported	reported as
										surgical		complication
	moderate (TOF 1-4)	31	1-111	43 (12,3)	8/23	Gastric bypass	Laparoscopy		Desflurane	conditions (King Score),		according to surgical
Fuchs-Buder T,et al ⁵²				10 (11)	, ==					improvement		conditions,
ai										29/34, 85,3%		not per group
												allocation
	deep (PTC 1-3)	34	I-III	45,2 (10,6)	9/25	Gastric bypass	Laparoscopy		Desflurane			
	moderate (TOF 1-2)	49	1-111	57 (20-77)	21/28	elective renal surgery	Laparoscopy		sevoflurane	surgical conditions L-SRS,	Pain NRS > 5: 31%	10%, (N=5)
Honing GHM, et al ⁵³	moderate (101 1 2)	43	' '''	37 (20 77)	21/20	ciccive renar surgery	саратозсору		Sevondrane	4,8 (0,4)	3170	
	deep (PTC 1-2)	49	1-111	51 (22-84)	20/29	elective renal surgery	Laparoscopy		sevoflurane			
	,			- , - ,						not reported	primary	not reported
										not reported	outcome QoR	not reported
											40 score	
											preop 191 (181-197),	
											POD1: 169	
											(154-182),	
											POD2 181 (172-186);	
											Pain scores	
											for shoulder	
W: 111154	moderate (TOF 1-2)	28	1-111	51 (41-58)	16/12	gastrectomy	robotic laparoscopy		desflurane		pain, abdominal	
Kim HJ, et al ⁵⁴											resting pain	
											and active	
											pain, analgetic	
											use: NS reported for 4	
											time frames,	
											how to summarize	
											this in this	
											sheet ?	
	deep (PTC 1-2)	28	1-111	57 (50-64)	19/9	gastrectomy	robotic laparoscopy		desflurane			
										primary	NRS	not reported
	moderate (TOF 1-2)	31	1-111	56,8 (9,6)	18/13	colorectal surgery	Laparascopy		desflurane	endpoint titrated average IAP 12,0	abdominal pain four time	
Kim MH, et al55		-			1 - 5, - 5					(0,5)	ppoints how	
		-									to resume ?	
	deep (PTC 1-2)	30	I-III	57,1 (7,7)	18/12	colorectal surgery	Laparascopy		desflurane			
King M, et al ⁵⁶	moderate (PLACEBO, no NMB)	61	I-II	62,3 (7,0)	61/0	radical retropubic prostatectomy	open		isoflurane	surgical field rating before	VAS 3,0 (2,8)	0%

				1		T	1	1		1 .		
										after study drug(1-4): treatment failure 17:61 (27,9%)		
	deep (TOF ≤ 1)	59	1-11	62,8 (7,6)	59/0	radical retropubic prostatectomy	open		isoflurane	17.01 (27,5%)		
Koo BW, et al ⁵⁷	moderate (TOF 1-2)	32	1-11	60 (12)	20/12	colorectal surgery	Laparascopy		desflurane	primary outcome IAP alarms 14/32; secondary surgical rating (1-5) acceptable 21/32	pain not reported separetly, acceptable patient satisfaction score 20/32	not reported
	deep (PTC 1-2)	32	1-11	58 (12)	19/13	colorectal surgery	Laparascopy		desflurane			
Koo BW, et a ^{ISS}	moderate (TOF 1-2)	32	1-11	48,5 (28-67)	13/19	cholecystectomy	Laparascopy	propofol TCI		primary outcome necessity to increase IAP, 11/32 (34,4%); secondary outcomeintraop patient mouvement 7/32 (21,9)	postop pain 24 h VAS 5 (0- 8); shoulder pain 24 h VAS 4 (0-10)	not reported
	deep (PTC 1-2)	32	I-II	45,1 (27-68)	19/13	cholecystectomy	Laparascopy	propofol TCI				
Koo CH, et al ⁵⁹	moderate (TOF 1-2)	54 (53)	1 - 11	70 (11)	46 / 7	transurethral resection of blad	lder	Propofol	Desflurane	1 = extremely poor, 2 = poor, 3 = acceptable, 4 = good, 5 = optimal		
	deep (PTC 1-2)	54 (51)	1 - 11	68 (10)	42 / 9	transurethral resection of blad	lder	Propofol	Desflurane			
Leeman M, et al ⁶⁰	moderate (TOF 1-2)	29 (factor design, lo high IAP)		49 (8)	5/24	Roux-en-Y gastric bypass	Laparascopy	Propofol	Desflurane	Directly after the procedure, the surgeon evaluated the overall quality of the surgical field on the Leiden-Surgical Rating Scale (L-SRS), ranging from 1 (extremely poor quality) to 5 (perfect quality)		
	deep (PTC 1-2)	33 (factor design, lo high IAP)		48 (13)	6 / 27	Roux-en-Y gastric bypass	Laparascopy	Propofol	Desflurane			
Madsen MV, et al ⁶¹	moderate (No NMB!)	14 (Crosso Trial> 7 with Int. a with Com	started and 7 p.)	44 (7)	7	Gynaecologic	Laparoscopy	Propofol	Propofol Maintenance	Intra-abdominal distance from the sacral promontory to the inserted trocar at pneumoperitone um of 12 mmHg		
	deep (PTC 0-1)	14 (Crosso Trial> 7		44 (7)	7	Gynaecologic	Laparoscopy	Propofol	Propofol Maintenance			

		with Int. a	ınd 7				I					
		with Com	p.)									
Madsen MV, et al ⁶²	moderate + 12 mmHg pneumoperitoneum ("sponataneous recovery". No fixed TOF count)	55 (50 analyze d)	1 - 11	48 (5)	0/55	Hysterectomy	Laparoscopy	Propofol	Propofol Maintenance			
	deep + 8 mmHg pneumoperitoneum(PTC 0-1)	55 (49 analyze d)	1-11	47 (5)	0/55	Hysterectomy	Laparoscopy	Propofol	Propofol Maintenance			
Madsen MV et al ⁶³	moderate ("sponataneous recovery". No fixed TOF count. ~ 10 mg Roc on request)	63	1 - 111	65 (35-85)	34 / 29	Laparotomy	open	Propofol	Propofol Maintenance	1 = extremely poor, 2 = poor, 3 = acceptable, 4 = good, 5 = optimal		
	deep (PTC 0-1)	65	1 - 111	63 (31-78)	38 / 27	Laparotomy	open	Propofol	Propofol Maintenance			
Martini CH, et al ⁶⁴	moderate (TOF 1-2)	12	11-111	median (IQR): 60 (24-70)	(10/2)	Prostatectomy	Laparoscopy	propofol	NA	S-point Leiden rating scale ranging from 1 (extremely poor conditions) to 5 (optimal conditions) (by surgeons during surgery and secondly by impartial anaesthesiologis t via video analysis) and duration of surgery	10 point-pain score postop in recovery room and length of stay in recovery room	N/A
	deep (PTC 1-2)	12	11-111	median (IQR): 59 (28- 74)	(10/2)	Prostatectomy	Laparoscopy	propofol	NA			
Ozdemir-van- Brunschot DMD, et al ⁶⁵	moderate (TOF 0-1)	19	NR	NR	(13/6)	donor nephrectomy	Laparoscopy with low-pressure PNP (6 mmHg)	propofol	sevoflurane	5-point Leiden rating scale ranging from 1 (extremely poor conditions) to 5 (optimal conditions), duration of surgery, blood loss, duration of pneumoperitone um; need to increase intraabdominal pressure, first warm ischemia time (WIT1),	postoperative pain scores (not defined) (different types of pain: superficial and deep wound pain and referred shoulder pain) 1h and 1d postop; opiate use on day 1 and cumulative opiate use after 48 h	Conversions to open procedure; intra-, and postoperative complications (such as bleeding, neuralgia, hypertension)
	deep (PTC 1–5))	15	NR	NR	(9/6)	donor nephrectomy	Laparoscopy with low-pressure PNP (6 mmHg)	propofol	sevoflurane			
Rosenberg J, et al ⁶⁶	moderate (TOF 2-3)	66 (subgro up 1: N=30	1 - 111	mean (SD): 46.1 (17.7); low pressure: 39.1 (13.6)	overall: 40/26	Cholecystectomy	Laparoscopy	propofol	NA	Surgeon's assessment of overall satisfaction with	11-point scale for postoperative pain score	adverse events (AEs)

		normal pressure ; subgrou p 2: n= 36 low intra- abdomi nal pressure)								surgical conditions during surgery (10-point scale)	within 24 h (also 1h,2h,4h, 48h, and on day 3- 8)	
	deep (PTC 1-2)	61 (subgro up 1: N=30 normal pressure; subgrou p 2: n=31 low intra-abdomi nal pressure)	1 - 111	mean (SD): 43.5 (15.76); low pressure: 46.7 (13.8)	overall: 39/22	Cholecystectomy	Laparoscopy	propofol	NA			
Soderstrom C, et al ⁶⁷	no nmb -> deep (TOF = 0, PTC > 1)	19	1-111	mean (SD): 57 (17)	NR	ventral hernia repair	Laparoscopy	propofol	NA .	5-point Leiden rating scale rating scale ranging from 1 (extremely poor conditions) to 5 (optimal conditions), change of conditions when switching NMB-technique; duration of surgery/suture time	NR	SAEs
	deep (TOF = 0, PTC > 1) -> no nmb	15	1 - 111	mean (SD): 55 (15)	NR	ventral hernia repair	Laparoscopy	propofol	NA			
Staehr-Rye AK, et al ⁶⁸	moderate (no measurement; 0.3 mg/kg IV rocuronium was given and neuromuscular function was allowed to recover spontaneously)	23	NR	median (IQR): 48 (35-59)	(10/15)	Cholecystectomy	Laparoscopy	propofol	NA	surgical space conditions (assessed by the surgeon as 1 on a 4-point scale); surgical space conditions on a numeric rating scale (NRS), where NRS 0 (optimal surgical space condition) and NRS 100(unacceptabl e surgical space conditions and an intervention was needed to	pain was evaluated as abdominal pain, incisional pain, shoulder pain, and overall pain using VAS (VAS 0 = no pain, 100 = worst possible pain) from the first postoperative assessment to 1 week after surgery, pain	AEs,SAEs, incidence of PONV

										secure acceptable surgical space)	at arrival in the postoperative care unit, 2 hours after surgery and 1 day after surgery, postoperative consumption of analgesics	
	deep (PTC 0 to 1)	25	NR	median (IQR): 45 (42- 49)	(6/17)	Cholecystectomy	Laparoscopy	propofol	NA			
Torensma B, et al ⁶⁹	moderate (TOF 1-2)	50	11-111	mean (SD): 47.2 (11.1)	(11/39)	elective Roux-Y-Gastric Bypass (bariatric)	Laparoscopy	propofol	NA	5-point Leiden rating scale rating scale ranging from 1 (extremely poor conditions) to 5 (optimal conditions), duration of surgery	11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (most pain imaginable) (measuremen t 4x in the PACU (at 10 main) to 10 (most pain) to 10 (most pain) to 10 (measuremen t 4x in the PACU (at 10 main) the value of the variable of the va	incidence of PONV
	deep (PTC 2-3)	50	11-111	mean (SD): 46.9 (10.6)	(9/41)	elective Roux-Y-Gastric Bypass (bariatric)	Laparascopy	propofol	NA			
Veelo DP, et al ⁷⁰	no NMB (on demand boluses rocuronium 0.30 mg·kg-1)	33	1-111	mean (SD): 63 (9)	(27/6)	esophagectomy	thoraco- laparoscopic	propofol	sevoflurane	5-point Leiden rating scale rating scale (extremely poor conditions) to 5 (optimal conditions) and surgical space conditions on a numeric rating scale (NRS), where NRS 0 (optimal surgical space condition) and NRS 100(unacceptabl e conditions); number of ondemand boluses of rocuronium	postoperative numerical pain rating (NRS) up to 12 hr postoperativel y	surgical events or complications intraoperative ly; surgical or anesthesia- related intraoperative adverse events; postoperative outcomes (such as complications, ICU length of stay, or mortality)

	deep (0.6 mg/kg/hr + on demand boluses rocuronium 0.30	33	I - III	mean (SD): 61 (9)	(28/5)	esophagectomy	thoraco- laparoscopic	propofol	sevoflurane		
	mg·kg-1)										í

Risk of Bias: